ReviewOncotarget2018
Breast cancer recurrence after reconstruction: know thine enemy.
Review in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Recurrence Patterns in Breast Cancer: A Single-Center Retrospective Analysis.Journal of clinical medicine · 2025Article
- Harnessing the power of physicochemical material property screening to direct breast epithelial and breast cancer cells.Bioactive materials · 2025Article
- Modified Keystone a Versatile Flap Reconstruction for Mastectomy Defects: Our Clinical Experience.Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India · 2025Article
- Breast Reconstruction- Developing a Volumetric Outcome Algorithm.Aesthetic plastic surgery · 2022Article
- Breast reconstruction following mastectomy in Indian women: a neglected entity.BMJ case reports · 2022Article
- Article
- Autologous fat grafting for breast reconstruction after breast cancer: a 12-year experience.Archives of gynecology and obstetrics · 2022Article
- Comparison of outcomes between immediate implantbased and autologous reconstruction: 15-year, single-center experience in a propensity score-matched Chinese cohort.Cancer biology & medicine · 2021Article
- Rates of Ipsilateral Local-regional Recurrence in High-risk Patients Undergoing Immediate Post-mastectomy Reconstruction (AFT-01).Clinical breast cancer · 2021Article
- [Breast reconstruction following cancer].Wiener klinische Wochenschrift · 2020Article
- Modeling and comparing data mining algorithms for prediction of recurrence of breast cancer.PloS one · 2020Article
- Delayed breast reconstruction with tram-flap and various modifications after radical mastectomy.Journal of medicine and lifeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast reconstruction proceeding cancer treatment carries risk, regardless of the type of surgery. From fat grafting, to flap placement, to implants, there is no guarantee that reconstruction will not stimulate breast cancer recurrence. Research in this field is clearly divided into two parts: scientific interventional studies and clinical retrospective evidence. The reconstructive procedure offers hypoxia, a wound microenvironment, bacterial load, adipose derived stem cells; agents shown experimentally to cause increased cancer cell activity. This is compelling scientific evidence which serves to bring uncertainty and fear to the reconstructive procedure. In the absence of clinical evidence, this laboratory literature landscape is now informing surgical choices. Curiously, clinical studies have not shown a clear link between breast cancer recurrence and reconstructive surgery. Where does that leave us? This review aims to analyze the science and the surgery, thereby understanding the oncological fear which accompanies breast cancer reconstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.